GlaxoSmithKline plc GSK and Theravance, Inc.
THRX today announced that the US Food and Drug
Administration (FDA) has approved BREO(TM) ELLIPTA(TM) as an inhaled
long-term, once-daily maintenance treatment of airflow obstruction in
patients with chronic obstructive pulmonary disease (COPD), including
chronic bronchitis and/or emphysema. It is also indicated to reduce
exacerbations of COPD in patients with a history of exacerbations.
BREO ELLIPTA is a combination of the inhaled corticosteroid (ICS),
fluticasone furoate "FF", and the long-acting beta2 agonist (LABA),
vilanterol "VI" (FF/VI 100/25 mcg).
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in